ISRG vs. MDT: Which Surgical Robot Stock Is the Smarter Buy?

Robotic surgery remains one of MedTech's fastest-growing battlegrounds, but not all players are competing from the same starting line. Intuitive Surgical ISRG continues to widen its lead as da Vinci procedure growth, system placements and recurring revenue reinforce the strength of its installed-base model. Meanwhile, Medtronic MDT is steadily building momentum with Hugo, pairing its robotics push with broader investments across digital surgery and surgical technologies.

The latest earnings highlight two distinct growth stories. Intuitive Surgical posted another quarter of double-digit revenue and procedure growth, supported by strong adoption of da Vinci 5, the single-port platform and the Ion lung biopsy system. Medtronic, on the other hand, delivered its strongest top-line performance in a decade while expanding Hugo placements, increasing system utilization and advancing U.S. regulatory milestones that could broaden the platform's reach.

The contrast raises an important question for investors: Is Intuitive Surgical's established robotics ecosystem still the superior long-term bet, or can Medtronic's diversified portfolio and expanding surgical platform narrow the gap over time?

Let's get into more detail to find out.

Price Performance

So far this year, Intuitive Surgical has plunged 34.4%, significantly underperforming Medtronic's 5.1% decline. The contrast is even sharper against the broader benchmarks, with the Medical sector gaining 6.2% and the S&P 500 advancing 11.4% over the same period.

ISRG's YTD Price Performance

Image Source: Zacks Investment Research

ISRG vs. MDT: Four Key Factors That Separate These Robotics Players

Commercial Momentum

Intuitive Surgical continues to set the pace in surgical robotics, with second-quarter 2026 revenues rising 19% and total procedures increasing 16%. The company's ecosystem remains the key differentiator as recurring revenue now accounts for 85% of sales, while the installed base approaches 13,000 da Vinci and Ion systems globally. Strong adoption of da Vinci 5, SP and Ion platforms reinforces a flywheel where higher procedure volumes fuel recurring instrument and service revenue.

Medtronic is generating healthy growth, but its robotics business remains at an earlier stage. Fiscal fourth-quarter revenues climbed 9.9%, marking the company's strongest annual top-line performance in a decade, while Hugo delivered procedure growth running two to three times the market alongside improving utilization. Unlike Intuitive Surgical, however, robotics remains one piece of Medtronic's much broader MedTech portfolio rather than its primary growth engine.

Product Innovation and Platform Expansion

Innovation remains central to Intuitive Surgical's leadership strategy. During the second quarter, the company expanded da Vinci 5 with the first wave of more than 100 planned software updates, advanced SP through broader stapler adoption, continued scaling Ion internationally and submitted a next-generation flexible robotic endoscope for FDA review. Management continues investing heavily across AI, imaging and robotics to widen the platform's long-term advantage.

Medtronic is aggressively expanding the Hugo ecosystem beyond the robot itself. The company launched Hugo for U.S. urology, submitted additional FDA clearances covering general surgery, gynecology and robotic vessel sealing, while growing its Touch Surgery digital ecosystem by more than 30% sequentially. Management is pairing Hugo with digital surgery, imaging and analytics capabilities to create a broader surgical platform over time.

Growth Runway and Market Expansion

Intuitive Surgical continues finding new avenues for expansion even as it dominates robotic surgery. International da Vinci procedures grew 20%, SP procedures surged 61% and Ion procedures jumped 36%, while markets like India, Japan and Europe provided fresh momentum despite ongoing pressure in China. The company is also pushing into newer areas such as cardiac procedures, nipple-sparing mastectomies and high-volume benign surgeries to extend its addressable market.

Medtronic's opportunity extends well beyond Hugo. The company is simultaneously expanding Affera in pulsed-field ablation, accelerating Symplicity for hypertension, growing Stealth AXiS in neurosurgery and pursuing tuck-in acquisitions across pain management and neurovascular care. This diversified approach gives Medtronic multiple growth drivers, although its surgical robotics opportunity is still in the early stages of commercialization.

Profitability and Investment Strategy

Intuitive Surgical continues balancing strong profitability with elevated innovation spending. The company delivered a 42% non-GAAP operating margin while increasing R&D faster than SG&A, reflecting management's willingness to reinvest from a position of financial strength. Healthy cash generation and a sizable cash balance provide flexibility to fund future product development without sacrificing operational discipline.

Medtronic is pursuing a different playbook by accepting near-term cost pressure to accelerate long-term growth. The company increased investments across R&D, commercial expansion, acquisitions and venture funding while absorbing tariff headwinds, yet still beat earnings expectations and guided for 6.75%-7.25% organic revenue growth in fiscal 2027. Management believes this investment cycle will strengthen leadership across several high-growth MedTech categories over time.

Estimates Picture

For 2026, the Zacks Consensus Estimate for ISRG’s bottom line is pegged at $10.74 per share, implying a 20.3% improvement over the 2025 reported figure.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for MDT’S fiscal 2027 bottom line is pegged at $5.94 per share, implying 7.4% growth over the 2025 reported figure.

Image Source: Zacks Investment Research

Valuation Comparison

ISRG currently trades at a forward 12-month P/E multiple of 32.26, above the Medical Instrument industry's 26.78, indicating the market continues to assign a premium to its long-term growth profile.

Image Source: Zacks Investment Research

MDT currently trades at a forward 12-month P/E multiple of 14.98, below the Medical Products industry's 17.74, suggesting a relatively attractive valuation compared with its peer group.

Image Source: Zacks Investment Research

Final Take: ISRG or MDT?

Intuitive Surgical appears to have the edge following the latest earnings, backed by stronger procedure growth, accelerating da Vinci 5 adoption and a high-margin recurring revenue model that continues to reinforce its leadership in robotic surgery. Medtronic, meanwhile, delivered its strongest top-line performance in a decade while making steady progress with Hugo, but its robotics business remains earlier in its commercialization journey.

From a Zacks perspective, both stocks carry a Zacks Rank #3 (Hold), suggesting investors may want to remain selective. ISRG stands out for its stronger Growth Score of B, while MDT offers the more attractive valuation profile with a Value and overall VGM Score of B. Investors seeking faster growth may lean toward ISRG, whereas those prioritizing value and diversification may find MDT the more balanced choice.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research